Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K
Lineage Commitment01:21

Lineage Commitment

4.6K
Commitment is the  process whereby stem cells:
4.6K
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

5
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
5

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A Novel CIP2A and BCL-XL Clinical Diagnostic Toolkit to Predict Disease Progression and Treatment-Free Remission in Chronic Myeloid Leukaemia.

International journal of molecular sciences·2026
Same author

Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.

British journal of haematology·2026
Same author

Pregnancy after hematopoietic stem cell transplant: an international multicenter study.

Blood advances·2026
Same author

Corrigendum to "Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group" [Modern Pathology. 2024;37(2):100406].

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia.

EJHaem·2025
Same author

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.

Leukemia·2025

関連する実験動画

Updated: Apr 19, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

慢性骨髄性白血病 (CML) とは

Jane F Apperley1

  • 1Department of Haematology, Imperial College London, London, UK.

Lancet (London, England)
|December 9, 2014
PubMed
まとめ

慢性骨髄性白血病 (CML) は,経口薬で治癒し,正常な寿命が提供されています. 進行中のCMLの病原性と標的治療に関する研究は,治療につながる可能性があり,他のがん治療の進歩につながる可能性があります.

科学分野:

  • 血液学 ヘマトロジ
  • 腫瘍学 腫瘍学
  • 分子生物学は分子生物学である.

背景:

  • 慢性骨髄性白血病 (CML) は,予後が悪い致命的な病気でした.
  • 分子病原性の理解における進歩は,CML治療に革命をもたらしました.
  • ターゲットを絞った治療法により,CMLは致命的な病気から,管理可能な慢性疾患へと変化しました.

研究 の 目的:

  • 慢性骨髄性白血病の現在の理解と管理を要約する.
  • CMLの分子基礎,診断,モニタリング,治療について議論します.
  • 持続的な検出不可能な疾患を通じてCMLの治癒を達成する可能性を調査する.

主な方法:

  • CMLのプレゼンテーション,病理生理学,診断技術のレビュー.
  • 標的型経口薬を含む,現在および新興の治療オプションの分析.
  • 治療の副作用,患者のアウトカム,およびモニタリング戦略の議論.

主要な成果:

  • CMLの予後は劇的に改善され,患者は口服薬で正常な寿命を達成しています.
  • 分子洞察に基づく標的型治療は,非常に効果的です.
  • 治療の実現の可能性 (安定した検出不可能な病気の治療) を調査中です.

さらに関連する動画

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.2K

関連する実験動画

Last Updated: Apr 19, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

31.2K

結論:

  • 生涯に渡る経口標的治療は,CMLを正常な寿命を持つ管理可能な疾患に変えました.
  • CMLの研究は,白血病発生を理解し,他の悪性腫瘍の治療法を開発するためのモデルを提供します.
  • ベンチ・リサーチをCMLのベッドサイド・クリニック・アプリケーションに迅速に翻訳することは,腫瘍学における加速的な進歩への希望を提供します.